Aditxt, Inc. is a social innovation platform accelerating promising health innovations. The Company operates four programs focused on autoimmunity, cancer and early disease detection, infectious diseases and women’s health. Its subsidiaries include Adimune, Inc. (Adimune), Pearsanta, Inc., Adivir, Inc. and Adifem, Inc. Adimune is focused on its immune modulation therapeutic programs. Adimune’s proprietary immune modulation product, Apoptotic DNA Immunotherapy (ADI), utilizes a novel approach that mimics the way its bodies naturally induce tolerance to our own tissues. Adivir, Inc. is focused on building a portfolio of antiviral and other antimicrobial solutions designed to target life-threatening viral infections and emerging pathogens. Pearsanta, Inc. is engaged in the development of molecular tests based on mitochondrial DNA to develop tests for early detection of cancer. It is also focused on addressing a critical challenge in cancer care: optimizing therapy selection.
Company Information
About this company
Key people
Amro A. Albanna
Chairman of the Board, Chief Executive Officer
Thomas J. Farley
Chief Financial Officer
Rowena Albanna
Chief Operating Officer
Shahrokh Shabahang
Chief Innovation Officer, Director
Corinne D. Pankovcin
Chief Mergers and Acquisitions Officer
Brian Brady
Independent Director
Sylvia Hermina
Independent Director
Charles Athle Nelson
Independent Director
Click to see more
Key facts
- Shares in issue904,468.00
- EPICADTX
- ISINUS0070258779
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$424,920.00
- Employees26
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.